Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01420432|
Recruitment Status : Unknown
Verified April 2011 by Shandong University.
Recruitment status was: Recruiting
First Posted : August 19, 2011
Last Update Posted : August 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Ankylosing Spondylitis||Biological: Human umbilical cord-derived MSCs||Phase 1|
Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The main clinical features are back pain and progressive stiffness of the spine. Oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. The current understanding of the pathogenesis of this disorder is limited.It mainly about to hereditary susceptibility (eg hla-b27),infection and autoimmunity.
Although traditional drugs, such as Nonsteroidal antiinflammatory drugs (NSAIDs) disease-modifying antirheumatic drugs (DMARDs such as MTX,SASP OR thalidomide) and steroids have been used in the treatment of AS, however, many studies have indicated that the overall response to these drugs is not satisfied. Addition, the severe side effects of these drugs have also been observed. The management of AS patients therefore remains unsatisfactory and targeted therapies are needed. Human MSCs isolated from human umbilical cord/placenta have been shown to have immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties. This study will evaluate the safety and effectiveness of MSC transplantation in the AS patients.
This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant +DMARDs therapy (experimental group) or DMARDs therapy (control group). Patients will undergo MSC transplant at the start of the study on Day 0. After 3 months, patients will receive the second MSC transplantation. After six and twelve months from the first transplantation, patients will be evaluated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Experimental: Human umbilical cord-derived MSCs and DMARDs
Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
Biological: Human umbilical cord-derived MSCs
1.0E+6 MSC/kg, IV drop and repeat repeated after three months
No Intervention: DMARDs
DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
- The Assessment of Spondyloarthritis International Society (ASAS)20 response [ Time Frame: 1 year ]
ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an abosolute change≥1 units on a 0-10 scale(0=no disease activity;10=high disease activity)for ≥3 domains,and no worsening in remaining domain.
Patient global Pain Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)
- erythrocyte sedimentation rate (ESR) [ Time Frame: 1 year ]erythrocyte sedimentation rate (ESR) level will be mainly observed after transplanting 3, 6,12-month.
- imageology [ Time Frame: 1 year ]imageology will be mainly observed after transplanting 3, 6,12-month.
- C-reactive protein (CRP) [ Time Frame: 1 year ]C-reactive protein (CRP) level will be mainly observed after transplanting 3, 6,12-month.
- Percentage of systemic T regulatory cell population [ Time Frame: 1 year ]Percentages of T regulatory cell population in peripheral blood will be tested in every 3 months after transplanting MSCs for one year
- Side effects [ Time Frame: 1 year ]Side effects were observed after the treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01420432
|Contact: chengyun zheng, Ph. Demail@example.com|
|Department of Hematology of the 2nd Hospital of Shandong University||Recruiting|
|Jinan, Shandong, China, 250033|
|Contact: chengyun zheng, Ph. D +86-531-85875635 firstname.lastname@example.org|
|Sub-Investigator: Ni Zhang|
|Principal Investigator:||chengyun zheng, Ph. D||Department of Hematology of The 2nd Hospital of Shandong University|